[Open clinical trial in dermal mycoses of a 1% ciclopiroxolamine solution in polyethylene glycol 400 carried out in FR Germany/Study with shortened therapy (author's transl)].

In an open multicentre study, a 1% solution of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, 2-aminoethanol salt (ciclopiroxolamine, Cic. Hoe 296, Batrafen) in polyethylene glycol 400 was examined for its topical activity in 344 cases of dermal mycoses. 65.4% of them were caused by dermatophytes and 19.2% by yeast-like fungi. In most cases, the treatment period was two weeks, with one or two daily applications. The examiners found global therapeutic effectiveness in 97.5% of the mycoses, the rate of very good and good results being 84.0%, and a very good tolerance in 99.0%. Individual side effects were predominantly subjective and transient.